Welcome to our dedicated page for Zivo Bioscience news (Ticker: ZIVO), a resource for investors and traders seeking the latest updates and insights on Zivo Bioscience stock.
Zivo Bioscience, Inc. (NASDAQ: ZIVO) is a biotechnology innovator focused on developing natural bioactive compounds derived from proprietary algal strains. This page serves as the definitive source for all official company announcements, research milestones, and strategic developments.
Investors and industry stakeholders will find timely updates including financial results, partnership agreements, regulatory filings, and scientific advancements. Our curated news feed provides essential insights into ZIVO's progress in nutraceutical research and biotech applications.
The page organizes content by key categories: quarterly earnings disclosures, product development breakthroughs, intellectual property updates, and corporate governance matters. Each news item is presented with clear context to help users assess material developments.
Bookmark this resource for streamlined tracking of Zivo Bioscience's advancements in algal-based biotechnology. Check regularly for verified updates directly from company filings and authorized communications.
Zivo Bioscience, Inc. (NASDAQ: ZIVO) announced a $1 million unsecured loan from its CEO, John Payne, to support working capital and a validation study for its coccidiosis treatment for broiler chickens. The loan has a 10% interest rate and includes warrants for 390,000 shares at $2.91 each. The company aims to validate its immune-modulating product, with results expected by mid-2023. Payne expressed confidence in Zivo's team and strategies, while CFO Keith Marchiando emphasized the significance of this support for funding beyond the current study. Zivo also continues to scale up production for the human food industry, showcasing its commitment to both animal and human health avenues.
FAQ
What is the current stock price of Zivo Bioscience (ZIVO)?
What is the market cap of Zivo Bioscience (ZIVO)?
